ArticlePloS one2026
Preventive effect of bentonite against pyoderma via direct binding capability of staphylococci.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bentonite, a naturally occurring clay mineral, is widely used for detoxifying mycotoxins and chemical contaminants, yet its potential interactions with microorganisms remain poorly characterized. Staphylococci, including Staphylococcus aureus in humans and Staphylococcus pseudintermedius in dogs, are major contributors to impetigo or pyoderma and other skin diseases, with rising antibiotic resistance underscoring the need for novel preventive strategies. This study investigated whether sodium bentonite directly modulates staphylococcal growth and associated inflammatory responses in vitro and in vivo. In bacterial culture assays, sodium bentonite showed a strong binding affinity for staphylococci, leading to significant reductions in viable colony counts. Pre-treatment of S. aureus and S. pseudintermedius with bentonite attenuated keratinocyte injury and markedly suppressed pro-inflammatory cytokine secretion, including IL-6, IL-8, and CCL2. In a murine pyoderma model, bentonite pre-treatment of S. pseudintermedius prevented lesion development, reduced bacterial burden, and downregulated cutaneous expression of TNFα, IL-1β, and IL-13, findings that were corroborated by histological improvements. Importantly, these effects extended to methicillin-resistant strains, highlighting a potential application against drug-resistant staphylococcal infections. By contrast, direct topical administration of bentonite gel in a murine atopic dermatitis model produced only modest benefits: ear swelling was reduced, but transepidermal water loss and clinical scores remained unchanged, suggesting limited therapeutic value in established chronic inflammatory conditions. Overall, sodium bentonite does not exhibit intrinsic bactericidal or anti-inflammatory properties but exerts protective effects through direct bacterial binding and subsequent inhibition of staphylococcus-induced cytotoxicity and inflammation. These findings identify sodium bentonite as a safe, non-antibiotic preventive option for staphylococci-associated skin diseases, particularly pyoderma, in both humans and companion animals. Future studies should further explore formulation strategies and delivery methods to optimize its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.